Lehrstuhl für Haut- und Geschlechtskrankheiten

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma (2026) Dummer R, Sandhu S, Miller WH, Butler MO, Taylor MH, Heinzerling L, Blank CU, et al. Journal article Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG (2026) Lallas K, Nanz L, Ugurel S, Mohr P, Meier F, Weichenthal M, von Wasielewski I, et al. Journal article Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study (2026) Gaughan EM, Kim M, Mendez I, Rao AD, Wei M, So A, Zhong X, et al. Journal article Vision transformer-based diagnosis of psoriasis and eczema in whole-slide histology (2026) Rivera Monroy LC, Petzold A, Sari M, Breininger K, Maier A, Vera González J, Erdmann M, et al. Journal article Vision transformer-based diagnosis of psoriasis and eczema in whole-slide histology (2026) Rivera Monroy LC, Petzold A, Sari M, Breininger K, Maier A, Vera González J, Erdmann M, et al. Journal article Harnessing Digital Pathology Tools to Distinguish Hand Eczema From Palmar Psoriasis: A Quantitative Approach (2026) Sari M, Schliep S, Petzold A, Kiesewetter F, Erdmann M, Sticherling M, Berking C, et al. Journal article esloco: simulation-based estimation of local coverage in long-read DNA sequencing (2026) Weich A, Lischer C, Vera J Journal article Complete lymph node dissection versus selective lymph node extirpation in melanoma patients with nodal macrometastasis and adjuvant systemic therapy (2026) Mayer KE, Hassel JC, Sambale J, Erdmann M, Sindrilaru MA, Oberschmied J, Thiem A, et al. Journal article NK cell-mediated tumor cell killing by bispecific innate cell engagers induces ADCC-mediated activation of primary human dendritic cells (2026) Heger L, Kaszubowski T, Amon L, Lehmann C, Wingert S, Medina-Echeverz J, Koch J, et al. Journal article Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy (2026) Dugas-Breit S, Forschner A, Erdmann M, Gutzmer R, Kähler KC, Holst I, Brekner A, et al. Journal article